| Title | Biphasic insulin aspart 30/70 (BIAsp 30): pharmacokinetics (PK) and pharmacodynamics (PD) in comparison with once-daily biphasic human insulin and basal-bolus therapy. | | Author(s) | Heise T, Heinemann L, Hövelmann U, Brauns B, Nosek L, Haahr HL, Olsen KJ | | Institution | Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany. | | Source | Diabetes Care 2009 Jun 1. | | Abstract | Objective: Pharmacological profiles of biphasic insulin aspart 30/70 (BIAsp30) once-daily (OD), twice-daily (BID) and three-times-daily (TID) were compared with other insulin regimens in two crossover glucose-clamp studies in insulin-treated type 2 diabetes patients.
Methods: Study 1: BIAsp30 OD, BID and TID vs. biphasic human insulin 30/70 (BHI30) OD (n=24). Study 2: BIAsp30 TID vs. basal-bolus (insulin glargine OD plus insulin glulisine TID) (n=24). Pharmacokinetics/pharmacodynamics (PK/PD) were investigated over 24h.
Results: Study 1: PK and PD were markedly different between BIAsp30 OD and BHI30 OD: maximum insulin concentration and glucose infusion rate (GIR) were higher for BIAsp30; time to maximum metabolism was 1.7h sooner for BIAsp30. Study 2: both regimens showed three distinct prandial-related GIR peaks. GIR 24h area-under-the-curve for BIAsp TID was higher than for basal-bolus: 2585.2 vs. 2289.2 mg/kg.
Conclusions: BIAsp had pharmacological advantages over BHI. BIAsp TID had a similar PD profile to basal-bolus. | | Language | ENG | | Pub Type(s) | JOURNAL ARTICLE
| | PubMed ID | 19487640 |
|
